A recent systematic review illustrated the potential role of Vitamin D (25OHD) supplementation in minimizing fibromyalgia syndrome (FMS)-related pain and chronic musculoskeletal pain (CMP), specifically in Vitamin D-deficient individuals. To examine whether Vitamin D deficiency is more common in CMP people and to investigate the role of Vitamin D on pain mitigation in these people, a systematic literature analysis of randomized controlled trials (RCT) was carried out.

For relevant RCTs, databases like Cochrane Central Register of Controlled Trials (CENTRAL), Physiotherapy Evidence Database, and PubMed were comprehensively explored. In total, 14 studies out of 434 that were accessed met the eligibility requirements. Vitamin D deficit is frequently witnessed in FMS and CMP people. A relationship between diffuse muscle discomfort and deficiency of 25OHD was substantiated in three trials, of which two provided the highest quality data.

Six studies showed that people with established blood 25OHD deficit may benefit from proper supplementation, with four of those studies having the strongest supporting data. Eight research, six of which provided the highest quality data, showed that supplementing with 25OHD reduces pain. Therefore, supplementation with Vitamin D appears to be valuable for people affected with CMP and FMS.